Roivant in the news and media

Roivant brings rare disease program closer as Immunovant CEO retires

“Monday’s realignment also marks a different strategy than Roivant has classically taken, as it generally prefers to house different experimental drugs in its own subsidiaries. The change has more to do with IMVT-1402 approaching a number of milestones and its importance, and isn’t a broader change in direction for Roivant, Gline said. Roivant said last month that a Phase 3 trial for IMVT-1402 in myasthenia gravis was expected to start in April.”

“IMVT-1402 has been a key focus for investors, and is seeing increased spotlight in the wake of last month’s news for another program called batoclimab. Roivant said in March that despite a Phase 3 success in the autoimmune disorder myasthenia gravis, it would not file an approval package for batoclimab because it believes IMVT-1402 can get similar efficacy results with a better safety profile.”

Immunovant replaces CEO, makes other changes as Roivant tightens control

“Immunovant was spun out of Roivant in 2019 to develop a pipeline of drugs to treat autoimmune disorders. While Immunovant is its own publicly traded entity, Roivant retains 57% ownership, giving it de facto control.”

“In March, Immunovant reported positive results from a clinical trial of an antibody treatment for myasthenia gravis. Those data supported the company’s decision to advance a next-generation antibody into Phase 3 studies for that condition and other autoimmune diseases, including Grave’s disease.”

Immunovant's muscle drug meets main goal, shares gain on new drug promise

“Immunovant said on Wednesday its experimental treatment for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer drug. 

In the late-stage study, batoclimab helped reduce levels of the immunoglobulin G (IgG) antibody, which plays a role in the weakening of muscles. While this was not the study's main goal, at least two analysts said the data bodes well for Immunovant's other drug, IMVT-1402, which could be even more effective.” 

Immunovant and Roivant succeed in trial of autoimmune drug 

“An antibody treatment from Immunovant and Roivant Sciences significantly reduced symptoms and disease activity in patients with generalized myasthenia gravis, a debilitating autoimmune disease — achieving the goals of a Phase 3 clinical trial.  

‘I feel fantastic about the quality of the dose response and I feel fantastic about the quality of the efficacy data,’ said Roivant CEO Matt Gline.” 

Datavant launches AI-powered platform for providers, payers 

“Datavant is beefing up its data retrieval network with a new layer of artificial intelligence that will allow health plans and risk-bearing providers to improve operations and patient care by accessing and analyzing a trove of clinical data.  
 
Value-based care arrangements require health plans and risk-bearing providers to navigate complicated requirements for managing patient data and monitoring population health. While providers and health plans face increasing cost pressure and administrative burden, Datavant touts that the enhanced platform will ease the administrative burden of locating and analyzing patient and member data.” 

Phase 2 trial of brepocitinib in cutaneous sarcoidosis planned

Roivant Sciences is planning to launch a Phase 2 clinical trial this year to test its experimental oral therapy brepocitinib in adults with cutaneous sarcoidosis.

The company said it expects to start the trial between April and June, and that the study’s results should become available in the second half of 2026. Roivant didn’t provide further details about the study’s design.

“Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in cutaneous sarcoidosis,” Matt Gline, CEO of Roivant, said in a company press release.

Top-line findings in Phase 3 batoclimab trial likely by late March

Top-line results from a Phase 3 clinical trial of batoclimab in people with generalized myasthenia gravis (gMG) are expected by the end of March, Roivant, which is developing the antibody therapy through its subsidiary Immunovant, reported.

The company said that trial findings will inform further decisions regarding next steps for batoclimab, as well as next steps in the development of Immunovant’s lead therapeutic candidate for the disease, IMVT-1402.

Roivant Sciences targets brepocitinib expansion with new cutaneous sarcoidosis trial amid $5.2B cash position

CEO Matt Gline highlighted 2025 as a year of major milestones, focusing on validating the anti-FcRn franchise with upcoming MG and CIDP data and a central registrational readout for dermatomyositis, which could lead to the commercial launch of brepocitinib. Additionally, the company has initiated a new brepocitinib trial for cutaneous sarcoidosis, marking its third indication for the drug.

Gline emphasized the strength of Roivant’s pipeline, which includes the FcRn franchise, brepocitinib, mosliciguat, and more, positioning the company for potential multi-blockbuster launches in the coming years.

10 Clinical Trials To Look Out For In 2025

Roivant’s Immunovant has two candidates [in myasthenia gravis], with Phase III data for the lead, batoclimab, from the FLEX study due to read out in the first quarter. Although the company has already said that it would prioritize its next-generation FcRn inhibitor, IMVT-1402, over batoclimab, the data are keenly awaited as a bellwether for the successor’s prospects and will be used by firm to inform its development. The decision to switch focus to IMVT-1402 followed encouraging Phase I data supporting best-in-class potential and a meeting with the FDA.

Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance

It’s show-me time for batoclimab, the FcRn-targeting antibody treatment from Immunovant and Roivant Sciences. A consequential Phase 3 study readout is coming before the end of the first quarter.

The study results in patients with generalized myasthenia gravis, a debilitating autoimmune disease, will help determine whether batoclimab — or another, more refined antibody also in Immunovant’s pipeline — can compete against Argenx’s Vyvgart, the current top-selling FcRn-targeting treatment.

Idorsia’s Tryvio deal delay; Galectin’s liver drug disappoints

Epitopea, Genevant ink cancer therapy pact: Epitopea will use Genevant’s lipid nanoparticle technology to develop RNA-based immunotherapies targeting certain proprietary tumor-specific antigens. The Canadian biotech could get up to $123.5 million in upfront and milestone fees for each product it makes with Epitopea.

Epitopea teams up with Genevant in $124 million deal

Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. The collaboration could see Genevant earn up to $124 million in upfront and milestone payments, alongside royalties on future sales. The companies aim to create mRNA-lipid nanoparticle therapies for an undisclosed cancer indication, with Epitopea gaining a nonexclusive global license to related delivery technology.

Oncology biotech Epitopea licenses Genevant nucleic acid delivery tech for up to $123M

To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery specialist Genevant Sciences in a deal worth up to $123.5 million. Genevant can earn that sum through upfront and contingent milestone payments per product along with tiered royalties on future sales, according to a Dec. 19 release. The goal of the deal is to develop new mRNA-lipid nanoparticle (LNP) therapies for an undisclosed cancer indication, the companies said.

Roivant unveils new ‘vant’ to take forward Bayer’s inhaled hypertension med

Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to a phase 2-ready pulmonary hypertension drug. … “Mosliciguat has the incredibly rare advantage of potential differentiation across three separate key areas—efficacy, safety and convenience in administration,” Roivant’s Gline said in a release.

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the transaction, which is expected to close in the fourth quarter of this year, as per an 18 September press release. Shares in both Organon and Roivant were down at close compared to their respective market opening prices on the day of the announcement.

Organon to Acquire Roivant’s Dermatology Subsidiary for Up to $1.2B

Organon has announced its plans to acquire Dermavant Sciences, a Roivant company focused on innovative immuno-dermatology treatments. The deal, which is expected to be finalized in the fourth quarter of 2024, will allow Organon to expand its dermatology offerings in the U.S. market, particularly with Dermavant’s flagship product, VTAMA (tapinarof) cream, 1%. VTAMA cream, a novel, non-steroidal topical therapy, was approved by the FDA in May 2022 for the treatment of plaque psoriasis in adults.

Organon to buy Roivant's dermatology unit for up to $1.2 billion

Women health-focused company Organon (OGN.N), opens new tab said on Wednesday it has agreed to buy Roivant's (ROIV.O), opens new tab unit Dermavant for up to $1.2 billion, expanding its reach to the skin disorder treatment market. Shares of Roivant, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However, Organon was down 1.4%.

Roivant dermatology subsidiary to be acquired by Organon

Organon has agreed to buy Roivant’s dermatology subsidiary Dermavant for $175 million upfront plus more than $1 billion in potential additional payments if certain milestones are hit. With the acquisition, Organon will gain Dermavant’s cream called Vtama, which was approved in 2022 to treat plaque psoriasis. The medicine is also awaiting action from the Food and Drug Administration that could expand its use to include atopic dermatitis, commonly known as eczema.

Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion

Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million, along with up to $1.025 billion in milestone payments. Organon, a Jersey City, N.J., healthcare company, said the deal expands its dermatology portfolio with the addition of Vtama, a non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and under FDA review for an additional indication to treat atopic dermatitis.

Roivant Flips a Skin Drug to Organon

On Wednesday, Roivant said it had sold both Dermavant and Vtama to Organon for $175 million up front, another $75 million if the FDA approves the drug to treat atopic dermatitis, and $950 million if the drug hits certain commercial milestones.

Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion

Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of its subsidiaries to pharma company Organon in a deal worth $1.2 billion. Organon is buying Roivant subsidiary Dermavant and its topical treatment Vtama. The drug is currently approved to treat various forms of the skin condition plaque psoriasis. But analysts and Organon see the real potential in Dermavant’s standing application with the Food and Drug Administration to expand the drug’s label to include atopic dermatitis, another chronic skin condition that affects around 25 million children and adults in the U.S.

Benzinga | Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon & Co has agreed to acquire Roivant Sciences Ltd’s Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology. Dermavant’s novel product, Vtama (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the FDA in May 2022. Vtama cream is a once-daily, steroid-free, topical therapy applied to affected areas.

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

Roivant is once again reaping the benefits of its bespoke business model. This time, it’s selling Dermavant to Organon for up to $1.2 billion. Most of that money — $950 million — is available via commercial milestones, according to Wednesday’s announcement. Organon is paying $175 million upfront plus another $75 million if Dermavant’s skin cream Vtama snags FDA approval to treat atopic dermatitis, a decision that’s expected by the end of the year. It will also pay tiered royalties on sales to Dermavant shareholders.

Roivant Deals Again, Sending Dermavant to Organon in Sale Worth Up to $1.2B

The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials. Roivant has struck another deal to sell one of its “vants.” This time around, the dermatology focused Dermavant will head to Organon in a deal valued up to $1.2 billion. Organon will be the new owner of Vtama, a non-steroidal topical therapy for plaque psoriasis that was approved in 2022. The cream is also currently under FDA review for atopic dermatitis, with a decision expected before the end of the year.

Promising Outlook for Roivant Sciences’ Mosliciguat in Treating PH-ILD: An Analytical Perspective

David Risinger’s rating is based on the promising potential of Roivant Sciences’ new Phase 2 program candidate, mosliciguat, which offers a novel treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). His confidence in the stock is further bolstered by the drug’s targeted delivery system and the strong Phase 1b trial results, which showed significant reductions in pulmonary vascular resistance and a favorable safety profile.

Roivant's new 'vant' emerges to advance Bayer lung drug

Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed from Bayer in a deal worth up to $294 million. Pulmovant is tasked with taking forward mosliciguat, an inhaled soluble guanylate cyclase (sGC) activator, which is being developed to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD), a disease with limited treatment options.

GSK discontinues herpes vaccine; Roivant launches new ‘vant’ around hypertension drug

Roivant has housed a blood pressure drug it licensed from Bayer in a new subsidiary dubbed Pulmovant that it created last year. The companies unveiled the drug and deal Tuesday, offering details on what they claim could be a “first-in-class and best-in-category” treatment for pulmonary hypertension that’s associated with interstitial lung disease. Bayer received $14 million upfront in return for global rights to the drug, called mosliciguat.

Roivant reveals Phase 1b results for new pulmonary treatment

Roivant Sciences (NASDAQ:ROIV) announced the promising results of the Phase 1b ATMOS study for mosliciguat, a potential first-in-class inhaled therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The study, which was presented at the European Respiratory Society Congress, showed that a single dose could lead to significant reductions in pulmonary vascular resistance (PVR).

Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug

Roivant Sciences is expanding its scope to the lungs, unveiling a new subsidiary whose main asset, licensed from Bayer, offers the potential to bring patients a novel treatment for a rare type of pulmonary hypertension currently served by only one FDA-approved therapy. The new Roivant company revealed Tuesday is named Pulmovant. Roivant, whose business model involves in-licensing drugs shelved by big pharmaceutical companies and then forming subsidiaries it calls “Vants” to advance their development, disclosed the new Vant and asset last year.

Roivant unveils new ‘vant’ to take forward Bayer’s inhaled hypertension med

Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to a phase 2-ready pulmonary hypertension drug. The asset in question, mosliciguat, is an inhaled soluble guanylate cyclase activator in development for pulmonary hypertension associated with interstitial lung disease (PH-ILD). As well as the upfront fee, Roivant has agreed to hand out up to $280 million in potential milestone payments to Bayer for the exclusive worldwide rights, on top of royalties.

Pharmalittle: We’re reading about a Roivant deal, limited access to medicines and more

Roivant has acquired from Bayer, the German pharma company, an experimental drug called mosliciguat that will be developed as a treatment for certain types of pulmonary hypertension, a family of serious lung diseases in which high blood pressure affects the arteries in the lungs and causes damage to the heart. Bayer was paid $14 million upfront by Roivant for global rights to mosliciguat and will be eligible for another $280 million in milestone-based payments, plus royalties on sales.

Roivant Sciences Unveils New Pipeline Program Mosliciguat

Roivant (Nasdaq: ROIV) today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder inhaler, at Pulmovant. Pulmovant presented data from the proof-of-concept Phase 1b ATMOS study during the ERS Congress in Vienna, Austria. “We believe mosliciguat can transform the lives of patients living with pulmonary hypertension, and I am excited to announce this potential first-in-class and best-in-category therapy.

Deals report: Roivant sets up Pulmovant to advance hypertension therapy

Roivant set up its newest subsidiary this week to house a hypertension program obtained via a licensing deal, while a large VC syndicate backed another start-up that will house two programs obtained via a pair of acquisitions. On Tuesday, Roivant Sciences Ltd. (NASDAQ:ROIV) said it had acquired exclusive, worldwide rights to sGC activator mosliciguat from Bayer AG (Xetra:BAYN) and created wholly-owned subsidiary Pulmovant to advance the molecule’s development.

Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer

Tuesday, Roivant Sciences Ltd. ROIV created Pulmovant to in-license from Bayer AG BAYRY exclusive worldwide rights to develop and commercialize mosliciguat. Bayer received an upfront cash payment of ~$14 million, with up to an additional $280 million agreed upon for future development, regulatory, commercial milestone payments, and tiered high-single-digit sales-based royalties. Mosliciguat is an inhaled, once-daily sGC activator with targeted delivery to the lungs via a dry powder inhaler.

Roivant Creates New ‘Vant’ to License Bayer’s Pulmonary Hypertension Drug

Roivant Sciences on Tuesday debuted its newest spinout venture Pulmovant, which will focus on the development of the investigational soluble Guanylate Cyclase activator mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease. In a deal also announced Tuesday, Roivant in-licensed worldwide rights to mosliciguat from Bayer for an upfront payment of $14 million and the promise of up to $280 million in future development, regulatory and commercial milestones. Bayer will also be eligible for tiered high-single digit royalties on mosliciguat’s sales.

Roivant creates Pulmovant to house lung disorder drug licensed from Bayer

Roivant on Tuesday announced Pulmovant, the latest Vant member in its organizational structure, to house a lung disorder therapy called mosliciguat in licensed from German conglomerate Bayer. U.K.-based Roivant (ROIV) advances its pipeline through a Vant structure designed to develop and commercialize its medicines and technologies. The company said Pulmovant will be created to hold the exclusive worldwide rights linked to
mosliciguat, a once-daily inhaled therapy targeted for lung delivery via dry powder inhaler.

Roivant’s Pulmovant Emerges After Stealth Development Plan

The company announced the launch of a new “vant” subsidiary focused on development of mosliciguat for pulmonary hypertension associated with interstitial lung disease.

Roivant acquires drug for pulmonary hypertension from Bayer

For months, investors have been asking Roivant Sciences chief executive Matt Gline to reveal the next drug it planned to buy with some of the $6 billion made from last year’s Roche deal. On Tuesday, Gline obliged. Roivant has acquired from Bayer, the German pharma company, an experimental drug called mosliciguat that will be developed as a treatment for certain types of pulmonary hypertension, a family of serious lung diseases in which high blood pressure affects the arteries in the lungs and causes damage to the heart.

Roivant unveils its next deal, hoping for TL1A-sized potential from a shelved Bayer lung disease therapy

Nearly a year after agreeing to a $7 billion-plus sale for an inflammatory bowel disease drug candidate, Roivant Sciences is pitching big potential in another drug from the back of a drugmaker’s closet. On Tuesday, Roivant said it has licensed global rights to mosliciguat, an inhaled lung drug previously discovered and developed by Bayer. The German pharma giant discontinued work in 2022 when it largely exited respiratory research. Roivant paid $14 million upfront, along with up to $280 million in potential milestone payments and possible tiered royalties in the high-single digits. The drug will be under a new subsidiary called Pulmovant.

Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers

Upstart innovative drugmaker Roivant Sciences takes a novel approach to creating and selling new pharmaceuticals. Roivant creates a subsidiary to develop and commercialize each drug. It calls its subsidiaries vants. On Thursday the Relative Strength Rating for Roivant stock rose from 68 to 71. The 71 RS Rating shows that Roivant stock outperformed more than 70% of stocks in IBD's database over the past year. It's a good but not yet great rating.

Health 2035 Summit

Roivant CEO Matt Gline on why he believes this is a good time to be hunting for assets on the shelves of big pharma, and upcoming catalysts. He describes why this may be a good time to asset hunt, but also why Roivant has been conservative with its cash. Plus upcoming catalysts in FcRN, TYK2xJAK1, GM-CSF, and more.

Roivant recently sold one spinout for billions. Is Priovant next?

When Roivant announced positive Phase 2 data of a key inflammatory drug back in April, the CEO of Priovant — the subsidiary in charge of development — started to get more calls. The drug, brepocitinib, was another Pfizer castaway that Roivant gleefully received, with Pfizer holding a 25% equity stake in Priovant. The April readout showed that the treatment failure rate for patients with non-infectious uveitis (NIU) given the higher 45 mg dose was 29%, described by Priovant CEO Ben Zimmer at the time as “better than any precedent study.”

Immunovant Shifts Focus to Other FcRn Inhibitor, Gives Rival Vyvgart Breathing Room

Immunovant, a spinout of Roivant Sciences, announced Wednesday that it is shifting its priority away from batoclimab, which is aimed at treating the autoimmune disorder myasthenia gravis, and is instead focusing on another anti-FcRn asset. IMVT-1402, an FcRN inhibitor unveiled at Roivant’s 2022 Investor Day, has been designated as the lead asset and is being targeted at Graves’ disease and other autoimmune disorders, based on “positive in-class data.”

CinRx Pharma Corrals $73M to Continue ‘Hub and Spoke’ Model of Startup Formation

CinRx operates a “hub and spoke” business model in which in-licensed drug assets are housed in separate subsidiaries, each one sharing in resources and management provided by the parent company. Others have pursued similar approaches, including Roivant Sciences, BridgeBio Pharma, and PureTech Health.

Immunovant Swaps Out Lead Assets

The Roivant-owned company plans to initiate a broad clinical trial program for IMVT-1402 in multiple indications, prioritizing it over batoclimab, which remains in Phase III development.

Risinger Recommends ‘Buy’ for Roivant Sciences with Optimistic Brepocitinib Revenue Forecast and Increased Price Target

Roivant Sciences, the Healthcare sector company, was revisited by a Wall Street analyst on May 29. Analyst David Risinger from Leerink Partners reiterated a Buy rating on the stock and has a $17.00 price target. David Risinger has given his Buy rating due to a combination of factors including the updated market model for Roivant Sciences’s brepocitinib to include its application in non-infectious uveitis (NIU), in addition to its use in dermatomyositis (DM).

CinCor’s ‘hub-and-spoke’ parent nabs new funding to build its next biotechs

Roivant Sciences sold subsidiary Telavant for $7 billion. Paragon Therapeutics has taken three companies public, led by Apogee Therapeutics, the top performing IPO since the start of 2023, BioPharma Dive data show. Nimbus Therapeutics inked a $4 billion deal with Takeda, too.

Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week

In a closely watched Phase 1 study, the highest dose of an experimental autoimmune drug developed by Biohaven reduced levels of the IgG autoantibody by 37%, a smaller magnitude of benefit than what investors were hoping to see. The therapy, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. Analysts wrote that, as of now, the Biohaven drug doesn’t look as competitive as other products under development by Argenx and by Immunovant and Roivant.

Biohaven protein-degrader drug falls short of investor expectations in early-study test

Immunovant and Roivant are developing two FcRN-targeted antibodies that have shown 75% depletion of IgG, albeit with multiple doses and over 21 days. In a research note, Stifel analyst Alex Thompson, who covers Immunovant, called the BHV-1300 data “underwhelming” and said they should “lift a near-term competitive overhang.” Shares of Immunovant were up 10% and Argenx rose 4% in reaction to the BHV-1300 data.

The top pharmaceutical companies by R&D expenditure

At the end of last year, the company joined the trending obesity market by spending $2.7bn to add an injectable dual GLP-1/GIP receptor agonist and an oral GLP-1 drug to its pipeline, through the acquisition of Carmot Therapeutics. Additionally, towards the end of last year, Roche also bought Roivant’s ulcerative colitis drug, RG-6631 (RVT-3101), for the high price tag of $7.1bn.

Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, Phase 2 Study Assessing Namilumab for Chronic Pulmonary Sarcoidosis

Roivant and Kinevant Sciences have recently announced the successful completion of enrollment in their Phase 2 study assessing namilumab's efficacy in treating chronic pulmonary sarcoidosis (RESOLVE-Lung). Sarcoidosis affects approximately 200,000 individuals in the U.S. and over 1 million globally, with the lungs being involved in about 90% of cases.

Roivant Sciences: Cashing In On Vants And Ventures

Roivant Sciences sold a subsidiary for $7.1 billion and plans a $1.5 billion stock buyback. Its pipeline includes promising drugs like IMVT-1402, despite some clinical risks. Financially, Roivant is well-capitalized with $6.67 billion in cash against minimal liabilities. Investment recommendation: Buy Roivant as part of a high-risk segment of a diversified portfolio.

Roivant spinoff tackles growing complexity of clinical trials

"The rise of biomarker-driven trials is adding new pressures on drug developers — from strictly defined inclusion criteria to growing scientific complexity that make enrollment targets harder to hit.

To better prepare for this type of clinical work, some companies are turning to study feasibility analyses, said Rohit Nambisan, CEO at Lokavant, a clinical trial intelligence platform that spun off from Roivant Sciences. "

Canaan hires Pfizer executive, reels in $100M for biotech investing

At Pfizer, Schoenbeck led the company’s Emerging Science & Innovation unit, which included the Centers for Therapeutic Innovation, an academic partnering group that brought forward medicines like a gut disease drug licensed to a Roivant Sciences subsidiary. The group was recently shuttered, Fierce Biotech reported Wednesday.

VC firm Canaan adds $100M-plus for biotech bets and tacks on a Pfizer vet to gauge early science

That initiative, in particular, helped introduce many new medicines to Pfizer’s pipeline, including an anti-TLA1 asset that was sold to Roivant, which flipped it to Roche for $7.1 billion. But a Pfizer spokesperson confirmed to Fierce Biotech yesterday that the unit's labs have been closed as part of a multi-billion-dollar cost-cutting plan.

Pfizer's academic-partnered R&D unit is scrapped as part of cost-cutting measures

Some of the medicines that have come out of the CTI program include an anti-TL1A program that Pfizer handed over to Roivant in 2022. The corresponding subsidiary that developed the program, Telavant, was bought by Roche for $7.1 billion in a deal announced last year. The CTI was also the source of Pfizer’s phase 3 IFN-β med, dazukibart, designed to treat dermatomyositis and polymyositis. The research came from scientists at Harvard Medical School and Brigham and Women's Hospital.

Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.

Roivant announces positive NEPTUNE study results for brepocitinib in non-infectious uveitis

Roivant and Priovant Therapeutics this week announced positive results from the Phase 2 NEPTUNE study (NCT05523765) evaluating brepocitinib in non-anterior non-infectious uveitis NIU. According to a news release, the NEPTUNE study enrolled 26 subjects with active NIU who were randomized 2:1 to brepocitinib 45 mg once daily or brepocitinib 15 mg once daily. Patients, physicians, and the study team were blinded to dose. All subjects received a 60 mg/day prednisone burst at study entry for two weeks and were tapered off prednisone per protocol by week 8 (6-week steroid taper).

Roivant and Priovant report positive data from non-infectious uveitis trial

Roivant and Priovant Therapeutics have announced positive outcomes from the Phase II NEPTUNE clinical trial of brepocitinib in non-anterior non-infectious uveitis (NIU). The double-blind trial involved 26 participants with active NIU, who were randomised into a 2:1 ratio to receive either brepocitinib 45mg or brepocitinib 15mg once a day. A 60mg per day prednisone burst was administered for two weeks at the start, followed by a six-week tapering off period.

Sumitomo Offloads Entire Stake in Roivant as Earnings Tank

Amid deteriorating earnings, Sumitomo Pharma is returning its entire stake in Roivant Sciences back to the UK-based company for US$648 million, or around 98 billion yen, with the transaction scheduled for early this month.

New data on liquid biopsy for colorectal cancer detection still underwhelms

Roivants’s eye drug brepocitinib, which it licensed from Pfizer, recently read out in a small study. The company also announced that it will buy back $1.5 billion in stock. These two bits of news make us ask the question: Will the company’s approach, which is to license shelved experimental drugs from large firms and further develop them, work? “Look, I think the truth is, there are pharma companies that, out of fear of looking stupid, don’t out license or partner their drugs,” Roivant CEO Matt Gline told STAT. “They just stick them in a bin somewhere.”

The biotech scoreboard for the second quarter: 32 stock-moving events to watch

Immunovant and Roivant are developing an FcRN-targeted antibody called batoclimab that aims to compete against Vyvgart, a similar approved drug from Argenx. A Phase 2 study in chronic inflammatory demyelinating polyneuropathy, or CIDP, an autoimmune nerve disorder, is expected mid year.

Roivant Sciences Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, $1.5B Share Buyback

Roivant and Priovant Therapeutics today announced positive results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date. Roivant also announced that its board of directors has authorized a share repurchase program for up to $1.5 billion of the company’s common shares, including the repurchase of all 71.3 million shares held by Sumitomo Pharma at a purchase price of $9.10 per share.

Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study

Roivant stock is nearing a breakout Tuesday after the biotech company announced positive results in an eye-disease study and a $1.5 billion share repurchase. The company enrolled 26 patients with noninfectious uveitis, a condition that causes inflammation in one or both eyes. Roivant Sciences (ROIV) measured the percentage of patients who failed to benefit from its treatment regimen after 24 weeks. Lower treatment failure is considered positive.

Roivant’s inflammatory med gets back on track with phase 2 eye disease data

Roivant’s autoimmune treatment impressed in a phase 2 trial, reporting treatment failure rates among patients with non-infectious uveitis (NIU) that executives touted as the best seen in active studies. The company, known for turning shelved pharma assets into valued medicines, believes it has struck gold once more, with Roivant's leadership using Tuesday’s readout to allude to brepocitinib’s blockbuster potential.

Roivant autoimmune drug succeeds in eye condition; company to buy back $1.5 billion in stock

A drug being developed by a Roivant subsidiary for a range of autoimmune conditions succeeded in a mid-stage trial in an eye disease that can ultimately lead to blindness, Roivant said Tuesday. Roivant, which has been flush with cash since selling a drug candidate to Roche last year for $7.1 billion, also announced Tuesday it was launching a $1.5-billion stock buyback initiative. The repurchase plan includes buying out Sumitomo Pharma’s entire stake in Roivant for $648 million.

Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study

Tuesday, Roivant Sciences and Priovant Therapeutics announced results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU). Roivant Sciences was founded by former Republican Party presidential candidate Vivek Ramaswamy. NIU is a group of disorders characterized by intraocular inflammation at different levels of the eye.

Roivant announces $1.5B share buyback, positive Phase 2 data

Shares of Roivant rose 6% in premarket trading Tuesday after the biotech group announced a $1.5B share buyback program and released positive data for its drug brepocitinib. Roivant’s board has authorized the company to buy back up to $1.5B common shares, including the repurchase of the entire Sumitomo Pharma stake for $648M. The Sumitomo stake repurchase will reduce the number of outstanding shares by 9%, Roivant said in a statement.

Positive NEPTUNE study results for Roivant’s brepocitinib in NIU

Switzerland-based Roivant Sciences and Priovant Therapeutics today announced positive results from the Phase II study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date. The drug was licensed to Priovant under a deal between Roivant and US pharma giant Pfizer (NYSE: PFE) in 2022. Analysts at Leerink Partners have previously forecast that brepocitinib

Roivant's anti-inflammatory drug succeeds in mid-stage study

Roivant Sciences, opens new tab said on Tuesday its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's shares up 8% in premarket trading. In the study testing 26 patients, 29% of those who received a higher-strength 45 milligram (mg) dose and 44% of those who received a 15 mg dose experienced treatment failure, with a lower rate implying a greater benefit from the drug.

Roivant announces study win in eye disease for Pfizer asset, plans $1.5B share buyback

Roivant has found a use for its extra cash, and is revealing the latest data from the big pharma relationship that helped generate those funds. On Tuesday, the drug developer made dual announcements that it was starting a $1.5 billion share repurchase program that will buy out a longtime insider. And it announced data from the Phase 2 trial of brepocitinib, a JAK1 and TYK2 inhibitor that it acquired through the same partnership with Pfizer that led to a separate $7.1 billion deal with Roche last year.

Roivant CEO: New deals could ‘materialize later this year’

Can Roivant’s business model survive its success? Roivant Sciences announced two pieces of news Tuesday: that its drug brepocitinib hit its goals in a 26-patient study in an eye disease called non-infectious uveitis, and that the company will be buying back $1.5 billion in stock, including a substantial number of shares owned by the Japanese drug giant Sumitomo.

JPMorgan's Take on Roivant Sciences (ROIV) Buyback and Positive Data Announcement

JPMorgan analyst Brian Cheng reiterated an Overweight rating on Roivant Sciences. The analyst comments "Before market open this morning, Roivant announced up to a $1.5bn stock buyback program and positive top-line data from its Ph 2 NEPTUNE brepocitinib study in non-infectious uveitis (NIU). We also spoke with ROIV’s CFO Richard Pulik before the company call at 8am. First, on brepocitinib data in NIU, we believe the data hit our home-run scenario as we laid out in our preview in mid-March (note).

Roivant Posts Phase II Eye Disease Win for TYK2 Drug, Plans Pivotal Program

Roivant has chalked up a mid-stage victory for its Pfizer-partnered dual TYK2/JAK1 inhibitor, setting it up to start a Phase III trial in non-anterior non-infectious uveitis this year. The oral drug candidate, brepocitinib, was one of the assets Pfizer transferred to Roivant’s Priovant Therapeutics in 2022. Brepocitinib targets TYK2, the receptor hit by Bristol Myers Squibb’s Sotyktu (deucravacitinib), and its sibling JAK1. Roivant is already testing the asset in a Phase III trial and ran the non-anterior non-infectious uveitis (NIU) study to learn whether to add a second pivotal program.

Roivant reveals positive immune drug data, share buyback plans

An experimental drug being developed by a subsidiary of Roivant Sciences succeeded in a Phase 2 trial testing it for a type of inflammatory eye condition called non-infectious uveitis, Roivant said Tuesday. Patients who received the drug, known as brepocitinib and licensed from Pfizer, had a meaningfully lower rate of “treatment failure,” a mixed measure of eye inflammation and other disease markers, than did those given placebo. Roivant claimed the findings surpass results for Humira, the only non-steroid treatment approved for the condition. No new safety concerns were reported, the company said.

Lawmakers want to add more Chinese biotechs to defense list

Roivant announced that an autoimmune drug it acquired from Pfizer succeeded in a Phase 2 trial. The drug blocks two proteins, including TYK2, a hot target for industry in the last couple years. Roivant also said it would spend up to $1.5 billion on a share buyback program, a little under half of which will be devoted to buying out its now-former partner Sumitomo. Ipsen licensed an antibody-drug candidate for solid tumors from Sutro Biopharma for $90 million in near-term payments and just over $800 million in longer-term milestones.

Roivant May Take On AbbVie In Uveitis With Strong Phase II Efficacy

Analysis Executive Summary Roivant’s brepocitinib bests data Humira previously posted in non-infectious uveitis, a top cause of blindness. The TYK2/JAK1 inhibitor also is in Phase III for dermatomyositis.

Investors fund Prometheus team's 'unfinished business' with $400M for new inflammatory biotech Mirador

The biotech’s anti-TL1A medicine PRA023 put 26.5% of recipients with ulcerative colitis into clinical remission by Week 12 during a midstage trial. Prometheus went up against Pfizer in the space, “outflanking” the pharma giant, which ended up divesting its TL1A program first to Roivant and then officially to Roche for $7.1 billion in October 2023.

Precision Medicine Startup Mirador Unveils $400M for R&D of New I&I Drugs

TL1A has become a hot target. Last fall, Sanofi began a partnership with Teva Pharmaceuticals focused on developing that company’s TL1A-blocking antibody. Weeks later, Roche paid $7.1 billion to acquire Telavant, a Roivant Sciences subsidiary with a Phase 3-ready TL1A-targeting antibody.

The top 10 pharma R&D budgets for 2023

The last few months of the year saw Roche put down $7 billion to add to its pipeline the regional rights to Roivant and Pfizer’s anti-TL1A antibody for bowel disease, which is on the cusp of phase 3. A few weeks later, Roche jumped into the obesity market with its acquisition of Carmot Therapeutics, which brought injectable dual GLP-1/GIP receptor agonists and an oral GLP-1 drug on board.

30 Biggest Biotechnology Companies in the World

Roivant Sciences Ltd. stands nineteenth among the top biotech companies known for innovative contributions to healthcare. They've developed novel treatments across various therapeutic areas, positively impacting patient outcomes. In Q4 2023, Roivant Sciences Ltd. reported an operating profit of 15,395 million CHF, with a net income of 12,358 million CHF. Core Pharmaceuticals sales reached 44,612 million CHF, while Diagnostics sales amounted to 14,104 million CHF.

Alumis Raises $259M Series C, Challenges BMS and Takeda for Autoimmune Markets

TYK2 inhibitors have a mixed record in SLE. The TYK2-JAK1 dual inhibitor Roivant picked up through a deal with Pfizer failed a Phase II trial in November but BMS has seen enough promise in its molecule to start a pivotal program.

With $86M Oversubscribed Public Offering, Absci Eyes 2025 IND for Lead Candidate

Telavant was jointly formed by Roivant Sciences and Pfizer in 2022 to develop and commercialize RVT-3101 in the United States and Japan. Telavant was 25%-owned by Pfizer, which held commercialization rights to the drug outside of those countries and previously sought to develop RVT-3101 under the name PF-06480605.

What biotech companies should know about M&A in down markets

Later during the panel, Mayukh Sukhatme, President & Chief Investment Officer at Roivant Sciences, observed, “There are two markets that are happening right now: the haves and the have-nots.” His observations are supported by the report, which found that “while the late stage assets (or biotech companies) enjoy a 73% premium one day post-announcement, 27% of biotechs in early stage development have less than one year of cash to sustain their operations.”

STATUS List: Matt Gline, Roivant CEO

Matt Gline landed Roivant Sciences, the drug firm founded by former GOP presidential candidate Vivek Ramaswamy, one of biotech’s biggest deals last year. In October, the company sold its experimental therapy for inflammatory bowel disease, RVT-3101, to Roche for at least $7.1 billion, having spent $50 million less than a year earlier acquiring the drug from Pfizer and investing in it for future late-stage trials. The deal put Gline on STAT’s list of the best biopharma CEOs of 2023. At the J.P. Morgan Healthcare Conference that kicked off 2024, Roivant’s business development team was already in search of the next big thing, meeting with pharmaceutical companies about existing drugs in their pipeline that they might be willing to hand off to Roivant to further develop.

TL1A Inhibitors Could Usher in New Era for IBD Treatment

Against this backdrop, two monoclonal antibodies targeting TL1A spurred major biopharma acquisitions in 2023. In June, Merck completed the purchase of Prometheus Biosciences for $10.8 billion. The company’s lead asset, PRA-023—now MK-7240—has shown clinical evidence of “best-in-class” potential for treating inflammation and scarring in the inflammatory bowel diseases (IBD) ulcerative colitis and Crohn’s disease, Nature reported. Then in October, Roche paid $7.1 billion for Roivant subsidiary Televant Holdings and its anti-TL1A antibody RVT-3101, also for IBD. That same month, Sanofi and Teva Pharmaceuticals announced a collaboration worth a potential $1.5 billion to co-develop TEV-’574, a TL1A inhibitor currently in Phase IIb clinical trials for IBD.

Dermavant’s Todd Zavodnick is moving derm into the digital world

Immuno-dermatology, stuck in a “cassette world” of steroid treatments, needs to move to the digital era, according to Dermavant CEO Todd Zavodnick, whose drug Vtama is the first FDA-approved non-steroidal cream for plaque psoriasis. Lecia Bushak provides an update on yet another PBM reform bill introduced in Congress, and how the PBM industry is responding.

5 Value Stocks In The Healthcare Sector

Roivant Sciences saw an increase in earnings per share from -0.4 in Q2 to $-0.21 now. Agile Therapeutics saw an increase in earnings per share from -3.1 in Q2 to $-1.47 now. This quarter, Exicure experienced an increase in earnings per share, which was $-0.7 in Q1 and is now $-0.68

Bristol Myers Squibb launches $674M drug discovery partnership with city biotech

VantAI, a Union Square-based biotech company founded in 2019, entered a $674 million partnership with Bristol Myers Squibb on Tuesday to discover potential new therapies. VantAI was founded in 2019 out of Roivant Sciences.

VantAI Enters Collaboration With Bristol Myers Squibb To Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence

VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb, a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest. The partnership leverages VantAI’s geometric deep learning capabilities with Bristol Myers Squibb’s expertise in targeted protein degradation to discover and develop new small molecule therapeutics. The collaboration will focus on leveraging VantAI’s generative AI platform to design molecular glues as small molecule therapeutics.

Roivant Sciences to Discontinue RVT-2001 Development in Myelodysplastic Syndrome

Development of the investigational SF3B1 modulator RVT-2001 (previously H3B-8800) will be discontinued based on findings from an interim analysis of the phase 1/2 Encore-MDS trial (NCT02841540) in patients with myelodysplastic syndrome (MDS), according to an announcement from developer Roivant Sciences. “Unfortunately, the data generated in the phase 1/2 study did not meet our bar for progressing,” Matt Gline, chief executive officer of Roivant, said during Tuesday’s investor call.

BMS signs $674m GenAI drug discovery deal with VantAI

Another week and another big pharma has enlisted the services of a generative AI company to accelerate drug discovery. In the latest deal, Bristol Myers Squibb (BMS) has entered a collaboration with US deep tech company VantAI. The partnership will focus on using VantAI’s generative AI platform (GenAI) to design and develop molecular glues – a type of small molecule that induces or stabilises interactions between two proteins that would not normally go together.

Stocks To Watch: Roivant Sciences Sees Relative Strength Rating Jump To 81

Roivant Sciences (ROIV) had its Relative Strength (RS) Rating upgraded from 77 to 81 Wednesday. While Roivant Sciences is not near an ideal buy point right now, see if it is able to form and break out from a proper chart pattern. Roivant Sciences reported 0% earnings growth last quarter. Revenue rose 118%. The company holds the No. 100 rank among its peers in the Medical-Biomed/Biotech industry group. Neurocrine Biosciences (NBIX) and Alkermes (ALKS) are also among the group's highest-rated stocks.

Roivant Sciences Third Quarter 2024 Earnings: Beats Expectations

Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) also surpassed analyst estimates significantly. Looking ahead, revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. The company's shares are up 3.9% from a week ago.

Markets Reeling From Stronger Inflation Report

Our cells have evolved a natural garbage disposal system, a group of special chemicals called “protein degraders” that break down unneeded junk in your body. On Tuesday, VantAI announced a $674 million deal with pharmaceutical giant Bristol Myers Squibb in the hopes of using cellular waste disposal processes, and its generative AI platform, to treat disease.

VantAI links up with Bristol Myers on molecular glue drug

US AI-enabled drug discoverer VantAI has entered into a strategic collaboration with pharma major Bristol Myers Squibb to discover new molecular glues for therapeutic targets of interest. The partnership leverages VantAI's geometric deep learning capabilities with Bristol Myers Squibb’s expertise in targeted protein degradation to discover and develop new small molecule therapeutics.

Dermavant Submits sNDA to FDA for Tapinarof Cream 1% to Treat AD Down to 2 Years

Dermavant Sciences recently announced its submission of a supplement new drug application (sNDA) to the FDA for tapinarof (Vtama) cream 1% for the topical treatment of atopic dermatitis in adults and children aged 2 years and older. Tapinarof cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, cosmetically elegant, and steroid-free, topical cream for both acute treatment and long-term management of atopic dermatitis.

InnovationRx: The Feds’ ‘Nutrition Labels’ For Healthcare AI

VantAI just announced a deal with Bristol Myers Squibb potentially worth up to $674 million. The goal? To use generative AI to design what are called "molecular glues." These glues bind to pathogens in the body, like cancer cells, connecting them to the protein degraders your cell uses to break down stuff it doesn't need anymore. Why AI? Because your body doesn't naturally use this process to fight disease, VantAI CEO Zach Carpenter explained to Forbes.

BMS signs $674M biobucks pact with Roivant-backed VantAI for molecular glues

Bristol Myers Squibb is offering Roivant-backed VantAI up to $674 million biobucks in a new partnership aimed at designing molecular glues as small-molecule therapeutics. The Big Pharma wants in on New York-based VantAI’s artificial intelligence platform in hopes of developing molecular glues, which are small molecules used to stabilize interaction between two proteins that don’t typically interact. The deal involves undisclosed targets of interest, but VantAI could receive up to $674 million in milestone payments plus royalties, and BMS also has the option to tack on additional therapeutic programs, according to a Feb. 13 news release.

This $674 Million Deal Aims To Turn Your Body's Garbage Disposal Into A Disease Fighter

VantAI has inked a partnership with pharma giant Bristol Myers Squibb that hopes to use the body’s cellular waste disposal processes to treat disease. The cellular processes that keep us alive produce a lot of waste. Which is why our cells have evolved a natural garbage disposal system, a group of special chemicals called “protein degraders” that break down unneeded junk in your body. They’ve recently emerged as a key area of interest for pharmaceutical companies, whose scientists are looking for ways to hijack this waste management system, Jersey mob style, and turn it against a variety of diseases.

Buy Rating for Roivant Sciences: Solid Sales and Promising Clinical Developments

Yaron Werber has assigned a Buy rating for Roivant Sciences based on a comprehensive evaluation of the company’s recent performance and future prospects. Werber’s positive outlook is influenced by Roivant Sciences’s inline sales performance of its product Vtama, which achieved $21 million in the third fiscal quarter, meeting expectations. Additionally, the company’s clinical development plan for IMVT-1402 appears robust and ambitious, with plans to initiate 4-5 pivotal trials by the end of FY24 and expand into 10 indications by FY25.

Roivant Shopping For Multiple, Transformative Deals

Roivant Sciences Ltd. is actively pursuing business development deals to build out its late-stage pipeline, with a goal of spending some of the cash it earned on the $7.1bn sale of Telavant to Roche Holding AG last year. CEO Matt Gline told investors during the company’s third quarter sales and earnings call on 13 February that Roivant hopes to bring in “multiple” programs over the next year that would be “transformative” to the late-stage pipeline.

Immunovant: An Intriguing And Developing Story

Today, we take a deeper look at Immunovant, Inc., a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for autoimmune diseases. The stock has been on a big run since last summer, as its primary pipeline asset is being evaluated in late stage studies against several potentially lucrative indications.

For biotechs in the industry’s handful of hot areas, it’s a seller’s market

TL1A, an inflammation target, also drove deals for Prometheus Biosciences and Telavant as both wrap up pivotal studies and near FDA submissions. Merck bought Prometheus for $10.8 billion — a 75% premium — while Roche acquired Telavant, a private company under Roivant, for $7.1 billion, after Roivant acquired the drug through a spinout deal with Pfizer.

Roivant's Matt Gline on the success of Telavant, Immunovant's FcRn program, and his expectations for the company's cash usage

Matt Gline reflects on learnings from the Telavant success, why he thinks Immunovant's FcRn might be best in class, and how Roivant's asset hunting has been going lately.

For biotech dealmakers, it’s everything, everywhere all at once

“I think it is interesting the extent to which we lionize that activity as sort of the end all, be all. That what success looks like for a biotech company is getting sold,” said Roivant Sciences CEO Matt Gline—who batted back rumors of his plans to sell the vant Immunovant. “I don't have a judgment on that. I think it's interesting, and I'm not sure it has always been true.”

JPM24: Biotech investors tip toe around the bear market to familiar territory

Roivant CEO Matt Gline says he's never been great at predicting capital access—he thought the pandemic would be tough to navigate, but that time period saw a boom in investing and goodwill towards the industry. But one thing is for sure: if you need it, it's hard to get.

JPM24: Roche's pharma BD chief explains renewed ADC interest but is spoilt for choice

Roche did appear to have spent more on later-stage candidates in 2023, including purchasing Roivant and Pfizer’s Televant for over $7 billion to get its hands on a phase 3-ready anti-TL1A antibody in bowel disease. Roche also splashed $310 million upfront to in-license Alnylam’s RNA interference hypertension candidate zilebesiran, which in September reported positive blood pressure data from a phase 2 trial.

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space

The pattern from testing in patients with ulcerative colitis suggests there could be a biological connection between the TL1A protein and other immunological conditions, says Mayukh Sukhatme, chief investment officer for Roivant. "Immunology is a surprising field and immunology is super complicated," he said. "Biology has a way of humbling everyone. We're very excited obviously. Roche and others in this field now are really excited about the extensibility of the drug into other indications and I think that the data set we have so far certainly encourages blue-sky thinking, but the experiments have to be run."

JPM24: Roivant’s Matt Gline has ‘pangs of regret’ for letting Telavant go, but he's ready to deal again

Sometimes, you have to act while the tea is hot. For Roivant CEO Matt Gline, that meant dealing out Telavant to Roche for $7.1 billion last year, even if he wasn’t quite ready to let the vant company go. “We weren't looking for an opportunity to sell a program last year,” Gline told Fierce Biotech on the sidelines of the J.P. Morgan Healthcare Conference Wednesday. “I was just talking to one of my colleagues about the pangs of regret for having sold it, even at that price, just because of how great the opportunity was,” he said.

JPM24: How Takeda beat 'almost every biopharmaceutical company' to win Nimbus’ TYK2 med

Evidence of the competitive landscape and pharma’s appetite for drugs under the immunology and inflammation (I&I) umbrella has been clear in the year since the deal closed, with Roche snapping up Telavant from Roivant for $7.1 billion and Merck & Co. paying $10.8 billion for Prometheus. Roivant also has brepocitinib, a dual TYK2/JAK1 med that recently failed a lupus trial but is gearing up for a registrational study in patients with dermatomyositis.

JPM24, Day 3: Gene editors talk business development; Roivant CEO has money to spend

Roivant's J.P. Morgan has a different vibe this year. After selling off Telavant to Roche for $7.1 billion last year, the company is flush with cash and not looking to raise funds, for once. "One of the things that we're often doing at J.P. Morgan is meeting with investors around raising money. We don't need to raise any money so we're still meeting with investors, but that has a different flavor to it," CEO Matt Gline said in an interview on the sidelines of the conference.

JPM Day 3 had a cautiously optimistic outlook

In an interview with STAT, Gline said Roivant’s licensing team has been meeting with pharma companies about existing drugs in their pipelines that may no longer fit with spending or research priorities, but which in Roivant’s hands could be developed further to create mutual value.

Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy

Roivant Sciences operates with an innovative business model through its subsidiaries, specializing in specific therapeutic areas such as immuno-dermatology and autoimmune disorders. Notable achievements include the sale of Telavant to Roche, the successful performance of Vtama cream for psoriasis, and advancements in clinical trials for atopic dermatitis and IMVT-1402 antibody development.

Roivant: Reinventing the Paradigm of Conventional Drug Development

Roivant is reinventing the discovery, development, and commercialization of new medicines. Mayukh Sukhatme, M.D. was recently appointed to Roivant's board of directors, and has served as Roivant’s President and Chief Investment Officer since January 2021. He is responsible for identifying, performing diligence on, devising development strategies for, and transacting on new therapeutic programs for the company. He also informs Roivant’s view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio.

Roivant’s Matthew Gline On Success, Failure And Finding An R&D Sweet Spot

Roivant achieved its greatest-ever success in selling RVT-3101 to Roche for $7.1bn – but not all investors are yet convinced by its unorthodox business model, and will be watching how it re-invests its new windfall.

Here are the best biopharma CEOs of 2023

Even with a late rally — thanks, Jay Powell — 2023 was a very challenging year for biotech. But there were bright spots, starting with Gline, who managed to create $5 billion from $50 million — in less than one year. Last December, Roivant essentially acquired an experimental treatment for inflammatory bowel disease called RVT-3101 from Pfizer for $45 million and then spent another $5 million to position the drug for future Phase 3 studies. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion. Of that, Roivant pocketed just over $5 billion in cash. Amazing.

Rise of the chief investment officer: Why the unique role works for Roivant

As Roivant’s chief investment officer, it’s Sukhatme’s job to be on the lookout for the company’s next program. So far his track record has been good. Programs he’s in-licensed or acquired have produced all 10 of the company’s positive phase 3 studies. In 2019, Roivant sold five of its subsidiaries to Sumitomo Dainippon Pharma in a $3 billion dollar deal that included assets later approved by the FDA. The growth of its subsidiaries and deals continued.

Immunovant takes on argenx, J&J with plans to test FcRn inhibitor in multiple parallel trials after PhI win 

Immunovant is gearing up to start a slate of mid-stage as well as pivotal trials for its follow-on autoimmune drug, IMVT-1402, after confirming what it calls “best-in-class” potential in a Phase I healthy volunteer study. Tuesday’s data update — on multiple ascending doses of 600 mg each — comes two months after news about the 300 mg cohort doubled Immunovant’s share price $IMVT and spurred a spike in the stock of Roivant $ROIV, which owns a controlling stake in Immunovant.

Roivant’s Matt Gline on raising capital and biotech’s outlook for 2024

2023 has been a busy year for Matt Gline, CEO of Roivant Sciences. Several subsidiaries in the biotechnology company’s “hub-and-spoke” network have produced promising clinical trial results, while Roche just paid $7 billion deal to acquire a gut disease drug from one of them. The data and the deal have improved Roivant’s position, giving it cash in a year when many of its peers have struggled to raise funding.

Today’s biotech news roundup, in under 800 words

A similar antibody for autoimmune diseases being developed by Immunovant, an offshoot of Roivant Sciences, continued to show promising results in an update from a study of healthy volunteers.

Immunovant gains after Phase 1 data for autoimmune therapy

Immunovant, a subsidiary of Roivant Sciences, announced Tuesday that IMVT-1402, its anti-FcRn antibody targeted at autoimmune diseases, caused dose-dependent and substantial reductions of IgG antibodies in a Phase 1 trial for healthy adults. According to initial trial data, IMVT-1402, designed to target IgG-mediated autoimmune conditions, cut IgG antibody levels by a mean of 74% at the 600 mg dose level after four once-weekly doses. Immunovant's other anti-FcRn antibody, batoclimab, at 680 mg, had previously led to a 76% mean reduction of IgG antibodies after four weekly injections.

Roivant Won’t Continue With Brepocitinib In Lupus After Phase II Failure

The company wants to focus efforts with the TYK2/JAK1 inhibitor in orphan rheumatology indications like dermatomyositis where current treatment options are inadequate.

NYC’s Ambition: Be A Premier Biotech Hub

"New York’s scale and dominance across a wide range of sectors – from fashion to finance to technology – are among the reasons it has been hard for the city to stand out as a biotech base, despite a wealth of academic and medical expertise. “New York doesn’t feel like a biotech hub,” Roivant CEO Matt Gline acknowledged. Roivant is headquartered in Times Square, but also has offices in South Boston, where he joked, “you walk out of the office and throw a stone and hit Vertex.”
"

The Endpoints Slack interview: Roivant CEO Matt Gline on playing moneyball in pharma, Vivek and politics, and the $7B Roche deal

As the ink dries on one of biotech’s biggest deals of 2023, Roivant Sciences CEO Matthew Gline popped in the secret Endpoints News Slack channel to discuss the latest with the wheeling-and-dealing biotech. The 39-year-old ex-Goldman Sachs banker shared his thoughts on the $7.1 billion deal with Roche, playing pharma “moneyball,” and lessons learned working at Lehman Brothers during its final days. There’s also, of course, Vivek Ramaswamy, Roivant’s charismatic founder-turned-presidential-candidate who Gline succeeded.

Roche’s $7B Roivant deal was a ‘moment of opportunity,’ CEO says

Roivant CEO Matt Gline and Telavant CEO Frank Torti know Roivant’s position as buyers and sellers in the pharma industry, and they’re embracing those opportunities. When Roivant CEO Matt Gline held a meeting with pharma giant Roche at the J.P. Morgan Healthcare Conference at the beginning of the year, he expected a brief one-on-one conversation with a member of the Swiss pharma’s team.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: did Pfizer miss out on Roivant/Roche deal?; Padcev/Keytruda combo impresses in bladder cancer at ESMO; biggest upfront ever in Daiichi/Merck deal; Rybrevant at ESMO; and subcu Leqembi could open up access.

Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise

How do cancer drugs work? What makes biotech stocks go up? And why are venture capitalists so optimistic? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week’s big oncology conference in Europe.

Roivant made $5 billion and fell 10%

With yesterday’s deal, Roivant Sciences turned about $50 million into $5 billion in less than a year, a dramatic feat of short-term value creation with no precedent in recent biotech memory. Then, as a reward, the company’s share price fell more than 10%.

Roche buys Telavant from Roivant for $7 billion, gaining bowel disease drug candidate

Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a promising experimental therapy for inflammatory bowel diseases.Telavant is owned by Roivant Sciences, with Pfizer holding a minority stake. The deal will allow Roche to develop the therapy, called RVT-3101, and, pending approval, sell it in the United States and Japan. Pfizer holds the commercial rights in other parts of the world.

Roivant’s CEO is a star, but even a blockbuster deal can’t escape biotech’s black hole

Roivant Sciences’ Matt Gline might be this year’s best biopharma CEO, and other thoughts about Monday’s blockbuster deal with Roche — like, why the heck did Roivant’s stock trade down? line created $5 billion from $50 million — in less than one year. Regular readers know that every December, I choose a best biopharma CEO. It’s a subjective award, but deal-making acumen, management skills, and delivering shareholder value are important measuring sticks. It’s still too early to call this year’s contest, but Gline is a front-runner.

Biggest stock movers today: Crypto-focused stocks, Roivant Sciences and more

Roivant Sciences shares rose 16% after the company announced that Roche will acquire Telavant Holdings for $7.1B upfront and a near-term milestone payment of $150M. The deal includes development, manufacturing, and commercialization rights for RVT-3101, a new therapy for inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Telavant was formed by Roivant (75% stake) and Pfizer (25% stake) to develop and commercialize RVT-3101 in the US and Japan.

Roivant/Roche: Did Pfizer Miss Out?

Pfizer gave US rights to an asset to Roivant, which turned around and sold it to Roche for $7.1bn 10 months later. Pfizer says it’s content with the 25% stake it will receive. Roivant CEO Matt Gline also talked to Scrip about the sudden turnaround.

Roivant CEO urges patience on future after $7B+ sale to Roche

Now that Roivant has ended months of rumors by signing a deal to sell its anti-TL1A inhibitor to Roche for $7.1 billion upfront, everyone wants to know how the company plans to spend that money. In an investor call Monday morning, analysts asked several questions about Roivant’s next steps. CEO Matt Gline stressed he and his team will “be patient” when it comes to finding the right opportunity. He didn’t go into specifics about when the money will be spent (or on what) and said it’s too early to decide what to do with the cash.

ROIV Stock Surges On $7.1 Billion Roche Acquisition Deal| Investor's Business Daily

Roivant Chief Executive Matt Gline says the TL1A drug class looks promising for patients with these stomach diseases that don't respond to popular anti-inflammatory treatments from AbbVie (ABBV) and Johnson & Johnson (JNJ). These drugs cut off inflammation earlier in the process. But that's using "a big hammer for a sharp nail," he told Investor's Business Daily in April. "The problem is because you're going after the top of that cascade, you wind up disrupting inflammation in a pretty wide variety of contexts, not necessarily just in the context you care about," he said. "So, these drugs have side effects."

Vivek Ramaswamy’s Former Company Is Doing Just Fine Without Him

Thanks to positive data from two promising drugs, the company’s shares have more than tripled over the past 12 months, recovering from an abysmal performance for much of 2022. The SPDR S&P Biotech ETF XBI -1.69% decrease; red down pointing triangle, meanwhile, is down 11% over that period. Last week, Roivant stock shot up after another vant in which it holds a majority stake, Immunovant, released results from an early study showing that its drug reduced the levels of a key immune marker in the blood while avoiding some key safety issues that had dogged the company in the past. Earlier this year, a drug being developed by another Roivant unit with Pfizer showed great promise in treating inflammatory bowel disease.

Immunovant (NASDAQ:IMVT) Sees Large Volume Increase Following Analyst Upgrade

Immunovant, Inc. saw unusually-strong trading volume on Thursday after Guggenheim raised their price target on the stock from $32.00 to $48.00. Approximately 1,220,811 shares traded hands during trading, a decline of 6% from the previous session’s volume of 1,303,665 shares.The stock last traded at $40.71 and had previously closed at $39.51.

The multi-billion dollar promise of efgartigimod and the broader FcRn inhibitor market

Thanks to promising candidates such as efgartigimod, the Fc receptor (FcRn) inhibitor market is poised to reshape the autoimmune disease treatment landscape. Sales projections for the market top $10 billion, as Driehaus Capital Management estimated in 2020.

Immunovant Prices $450M Common Share offering At $38/Share, With 7,370,000 shares offered To public and 4,473,684 to Roivant Sciences

The Street Is Finally Waking Up To Roivant Sciences Ltd

After-hours trades for Roivant Sciences Ltd (ROIV) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.18, or -1.36%, to $13.01. The Roivant Sciences Ltd has recorded 1,282,622 volume in the after hours trading session.

Immunovant's $450M; Oncopeptides reassesses Pepaxti strategy in Europe; Akebia resubmits kidney drug

Immunovant goes for $450M: Immunovant’s early-stage autoimmune data will lead to a $450 million haul for the New York biotech, about $150 million more than initially announced on Tuesday. Immunovant said Wednesday it plans to sell 7.37 million shares $IMVT at $38 apiece in a public offering and sell another 4.47 million to its parent, Roivant Sciences. The early clinical data for Immunovant’s anti-FcRn IMVT-1402 sent the company’s shares soaring on Tuesday and also boosted Roivant’s stock price.

Immunovant (IMVT) Prices 7.37M Share Offering at $38/sh

Immunovant, Inc., a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten public offering and concurrent private placement, with anticipated gross proceeds to Immunovant of approximately $450 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transactions.

Immunovant to raise $450M on 'potent' falls in IgG levels with MAb in phase I

Immunovant Inc. is seeking a $450 million windfall on the back of the “best-in-class potential” of its early stage monoclonal antibody for IgG-mediated autoimmune diseases, IMVT-1402, which a phase I readout demonstrated could supersede the firm’s lead, batoclimab.

Immunovant: Immune Boost, From Clinical Trials To An Aggressive Bullish Stock

Although Immunovant's stock has rallied around 100% since January, recent data on its therapeutic candidate, IMVT-1402, has further bolstered confidence, and we expect more upside from here.

Immunovant Parlays Its Argenx-Rivaling Shot Into A Huge Offering

Immunovant stock surged again Wednesday after the drugmaker announced a $300 million offering on the heels of promising test results for an autoimmune disease treatment. The company plans to offer a total $300 million in common stock through a public offering and a private placement. That includes $130 million in common stock. Immunovant will also give the underwriters a 30-day option to buy up to $19.5 million in shares.

Roivant Sciences stock could go higher on monetization potential of ‘blockbuster’ assets

Roivant Sciences shares finished more than 20% higher on Tuesday after Immunovant, in which Roivant holds a 56.5% stake, released positive data from an early-stage study of its key asset IMVT-1402, a FcRn inhibitor being developed to treat a range of autoimmune diseases.

Théa won't buy ProQR's ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October

Immunovant’s $130 million offering: Immunovant’s early-stage autoimmune data, viewed by analysts as a potential catalyst for a sale or other transaction, spurred a major financing haul for the New York biotech. It presented data on its anti-FcRn IMVT-1402 Tuesday morning. Later that day, it disclosed plans for a $130 million public offering and a $170 million boost from its parent, Roivant Sciences.

Immunovant upped on positive trial, Docusign raised to Hold: 5 big analyst picks

Raymond James upgraded Immunovant (NASDAQ:IMVT) to Outperform from Market Perform with a price target of $40.00 following the release of both Single Ascending Dose (SAD) and preliminary Multiple Ascending Dose (MAD) data for its next-generation anti-FcRn therapeutic, IMVT-1402. As a result, shares jumped more than 97% yesterday.

Immunovant stock rallies for second day, fueled by public offering, drug data (IMVT)

Immunovant (IMVT) stock rallied for the second day, fueled by news it was planning to offer $300M of its common shares and positive data for its drug candidate IMVT-1402.

Immunovant’s autoimmune drug shines in Phase 1 study, surprises analysts

Immunovant’s next-generation anti-FcRn therapeutic IMVT-1402 posted a clean safety profile in a Phase 1 study, but a surprise disclosure in Tuesday’s topline reveal also served to differentiate it relative to the Roivant subsidiary’s first-gen asset.

Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29%

Immunovant's first-generation drug — still in testing — caused increases in albumin and LDL cholesterol. Promisingly, Immunovant said Tuesday its second-generation approach didn't lead to the same increases

Roivant Sciences Ltd. Moves 21.6% Higher: Will This Strength Last?

Roivant Sciences Ltd. shares rallied 21.6% in the last trading session to close at $12.41. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 9.6% loss over the past four weeks.

Why Immunovant Stock Is Bolting Higher Today

Shares of Immunovant, an autoimmune specialist and subsidiary of Roivant Sciences, are showing no signs of cooling off after nearly doubling in value on Tuesday. Specifically, the drugmaker's shares were up by another 5.3% on sky-high volume as of 11:27 a.m. ET Wednesday morning. Roivant Sciences stock is also up for a second straight day, with the drugmaker's shares rising by as much as 6.6% in early-morning trading.

Immunovant shares surge after antibody treatment succeeds in early-stage study

Shares of Immunovant surged over 60% in premarket trading on Tuesday, after the drug developer said its antibody treatment succeeded in an early-stage trial. Immunovant's experimental drug reduced the levels of IgG, or immunoglobulin antibodies, that cause inflammation and disease.The company is developing its antibody drug, IMVT-1402, as an under-the-skin injection to potentially treat autoimmune diseases.

These 2 Biotech Stocks Are Bucking a Down Market Tuesday

Shares of Immunovant soared 60% in premarket trading on Tuesday morning. The immunology specialist reported results from an early clinical trial that included encouraging data about a key treatment's potential for helping to treat a wide variety of autoimmune diseases.

Early data are promising for autoimmune disease drug from Roivant Sciences’s Immunovant

“This is the best possible scenario for this data, and it leaves a wide range of possible paths forward for this drug,” Roivant CEO Matthew Gline told STAT ahead of Tuesday’s announcement. “We think it really has the possibility to reach many, many patients in many, many different diseases.”

Immunovant data show potential for autoimmune disease drug

Shares in New York-based biotechnology company Immunovant and its main shareholder Roivant Sciences jumped higher Tuesday after Immunovant disclosed early clinical results for a closely watched autoimmune disease drug.

Immunovant shares surge as early antibody treatment data beats expectations

Shares of Immunovant (IMVT.O) more than doubled on Tuesday after early-stage data from its experimental antibody treatment exceeded analysts' expectations.

Buy Rating for Roivant Sciences: Positive Drug Trials and Promising Future Developments

Roivant Sciences (ROIV) has received a new Buy rating, initiated by Goldman Sachs analyst, Corinne Jenkins. Corinne Jenkins has given Roivant Sciences a Buy rating due to several key factors. Firstly, the recent positive Ph1 single ascending dose (SAD) and initial multiple ascending dose (MAD) data of IMVT’s IMVT-1402, a significant asset in which ROIV holds a 57% stake, had a minimal impact on albumin/LDL cholesterol.

Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

- IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab
- No decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohort
- IMVT-1402 is being developed as a simple SC injection

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in IgG in initial data from a Phase 1 clinical trial in healthy adults, with no dose-related changes in serum albumin or LDL-C, bolstering IMVT-1402 as a potential best-in-class neonatal fragment crystallizable receptor (FcRn) inhibitor.

Vivek Ramaswamy's Roivant jumps 19% on positive IMVT trial data

Roivant Sciences, the biotech company founded by Vivek Ramaswamy, reported today promising results from a Phase 1 clinical trial involving the subcutaneous administration of IMVT-1402.

Immunovant and Roivant jump as new drug shapes up to become blockbuster

Shares of Immunovant surged 59% after the company revealed encouraging data from an early-stage study of its key asset, IMVT-1402, being developed to treat a host of autoimmune diseases.

Roivant's FcRn inhibitor avoids cholesterol problem, which clouded CEO Gline's first days in the gig

Roivant CEO Matt Gline learned just days into his new gig in 2021 that immunology offshoot Immunovant had a cholesterol problem with its lead asset. Now, the concern that sent him immediately spiraling into "crisis management mode" has come full circle, as a next-gen candidate nailed key biomarker figures in a phase 1 trial.

Immunovant soars on early data for IMVT-1402

Shares of Immunovant (Nasdaq: IMVT) were up a massive 80% at $36.63 by mid-morning, after the Roivant Sciences company released data from an early study of an autoimmune disease drug.

Wall St slides as rate concerns keep Treasury yields near 16-year peak

In company news, Immunovant (IMVT.O) shares surged 97% after early-stage data from the drug developer's experimental antibody treatment exceeded analysts' expectations.

Immunovant Doubles — And Slugs Argenx — As Autoimmune Disease Battle Heats Up

Immunovant (IMVT) said Tuesday its drug lowered a key antibody in healthy people, signaling it could treat a myriad autoimmune conditions, and IMVT stock launched to a two-year high.

Roivant’s FcRn antibody for autoimmune disease shows early potential in healthy subject PhI trial

Roivant Sciences’ Immunovant has unveiled biomarker results for its autoimmune disease antibody drug from a Phase I healthy subject trial. Immunovant’s stock price $IMVT soared by 62% to $34 pre-market in response to the data release, while Roivant $ROIV — which owns a controlling share of Immunovant — went up by 15% to $11.60.

Immunovant stock climbs on Phase 1 data for autoimmune drug

Immunovant, Inc. jumped ~34% in the pre-market Tuesday after announcing data from a Phase 1 trial for its second product candidate, IMVT-1402, targeted at IgG-mediated autoimmune diseases. Its parent, Roivant Sciences, added ~10% in reaction.

Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today?

Immunovant Inc IMVT, a unit of Roivant Sciences Ltd ROIV, announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG) in initial data from a Phase 1 trial in healthy adults, with no dose-related changes in serum albumin or LDL-C.

Updated: Roivant’s FcRn antibody for autoimmune disease shows early potential in study with healthy subjects

Roivant Sciences’ Immunovant has unveiled biomarker results for its autoimmune disease antibody drug from a Phase I healthy subject trial. The subcutaneous drug, dubbed IMVT-1402, targets the neonatal fragment crystallizable receptor (FcRn) for immunoglobulin G (IgG)-mediated autoimmune diseases.

Immunovant Stock Soars on Positive Phase I Autoimmune Antibody Data

Investors were buzzing Tuesday morning on the release of positive initial Phase I data for Immunovant’s autoimmune antibody, sending stock prices up over 60% in premarket trading on the news.

Roivants Shares Surge on Positive Results of IMVT1402 Phase 1 Trials

Roivant’s shares experienced a surge in trading activity following the company’s exciting announcement regarding the positive initial results of their IMVT-1402 Phase 1 SAD and 300 mg subcutaneous MAD trials. IMVT-1402 is Roivant’s second product candidate aimed at targeting autoimmune diseases by inhibiting the neonatal Fc receptor (FcRn).

Roivant sales rise but miss expectations in Q2

In its quarterly earnings report released Monday morning, Roivant Sciences said that sales rose from $4.3 million in the same quarter in 2022 to $21.6 million. The sum, however, fell short of analyst expectations of $24.5 million.

Roivant Sciences Fiscal First-Quarter Loss Narrows Less Than Expected as Costs Widen

Roivant Sciences' (ROIV) fiscal first-quarter results missed Wall Street's
estimates, as the biotechnology company logged an increase in its overall
operating costs.

Roivant Sciences Reports Steep Losses and Lighter-Than-Expected Sales

Roivant Sciences, a leading biotech stock founded by presidential
candidate Vivek Ramaswamy, announced significant losses and
lower-than-anticipated sales during the second quarter. This news is expected to cause a decline in ROIV stock.

Retail Outlook Lifts Wall Street Pre-Bell; Asia Down Europe Up

Roivant Sciences plans to report earnings pre-bell, among others.

Roivant CEO hints at more deals shaping up as key Immunovant data loom

Roivant Sciences has more potential asset deals in the works — after setting up two Vants around Pfizer assets in the past two years — and hopes to be talking about them in 2024, CEO Matt Gline told analysts on a quarterly earnings call on Monday morning.

Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales

Top-notch biotech stock Roivant Sciences — founded by presidential candidate Vivek Ramaswamy — reported steep losses and lighter-than-expected sales on Monday. ROIV stock is likely to tumble.

Roivant Sciences reports higher-than-expected FQ1 loss

Roivant Sciences has released its financial results for the first quarter, falling short of analyst expectations.The company reported earnings per share (EPS) of ($0.38), which is $0.10 worse than what analysts had predicted at ($0.28). Revenue for the quarter reached $21.62 million, lower than the consensus estimate of $24.77M.

Roivant Sciences Ltd. 2023 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Roivant Sciences Ltd. in conjunction with their 2023 Q1 earnings call. (Earnings presentation transcript)

Roivant Sciences earnings come in below Street estimates despite VTAMA sales growth

Roivant Sciences shares traded modestly higher after the inflammation and immunology-focused biopharmaceutical company reported fiscal first-quarter financial results that fell short of expectations for both earnings and sales.

Roivant Sciences reports higher-than-expected FQ1 loss

Roivant Sciences Ltd. has released its financial results for the first quarter, falling short of analyst expectations.

Roivant Sciences earnings missed by $0.10, revenue fell short of estimates

Roivant Sciences reported second quarter EPS of $-0.380, $0.10 worse than the analyst estimate of $-0.280. Revenue for the quarter came in at $21.62M versus the consensus estimate of $24.77M.

A deal? An asset sale? A launch? Everyone is watching next moves for Roivant, BridgeBio

What’s next for two of biotech’s once-cool, now-hot companies? Hot on the heels of critical data readouts, Roivant Sciences and BridgeBio Pharma are enjoying two of 2023’s most dramatic stock turnarounds, after their briefly-out-of-favor business models have turned up potential blockbuster drugs.

Biotech Hangout

A weekly discussion of all things biotech – breaking news, data deals and FDA actions – with a community of biotech industry leaders and experts.

Swelling losses haven't held back gains for Roivant Sciences (NASDAQ:ROIV) shareholders since they're up 156% over 1 year

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right business to buy shares in, you can make more than you can lose. Take, for example Roivant Sciences Ltd. (NASDAQ:ROIV). Its share price is already up an impressive 156% in the last twelve months.

Best Workplaces for Innovators 2023: Science and technology

Newly minted graduates who join the biotech company enter a two-year rotational program where they spend six months with four different teams in various functions across the dozen different companies within the Roivant portfolio.

Dealmaking Gives Biotechs Needed Financial Relief, But Deal Terms Are Under Pressure

Roivant Sciences Ltd. CEO Matt Gline said during the same panel discussion that as a company that often licenses or acquires external drug candidates, “the last couple of years has been one of the best
environments for that kind of dealmaking in history, frankly, because people have fewer options. And so, if you can be one of their options, you're in a privileged position.”

Roivant Sciences's Return on Invested Capital Insights

According to Benzinga Pro data, during Q4, Roivant Sciences posted sales of $27.38 million. Earnings were up 84.19%, but Roivant Sciences still reported an overall loss of $60.86 million. In Q3, Roivant Sciences brought in $17.05 million in sales but lost $384.90 million in earnings.

Analysts Just Made A Significant Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts

Roivant Sciences Ltd. (NASDAQ:ROIV) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects.

Is Roivant Sciences (ROIVW) a Winner in the Healthcare Sector?

Roivant Sciences (ROIVW) is around the top of the Healthcare sector according to InvestorsObserver. ROIVW received an overall rating of 78, which means that it scores higher than 78% of stocks. Additionally, Roivant Sciences scored a 71 in the Healthcare sector, ranking it higher than 71% of stocks in that sector.

Roivant Sciences GAAP EPS of -$0.20 beats by $0.18, revenue of $27.38M beats by $9.18M

Why Shares of Roivant Sciences Rose Wednesday

Roivant reported fourth-quarter revenue of $27.4 million, up 197% year over year, and an earnings per share (EPS) loss of $0.05, compared to an EPS loss of $0.39 in the same period a year ago. The improved EPS is really what propelled the stock higher.

Roivant Sciences Surprises Investors with Impressive Q4 Performance Leading to Stock Surge

On June 28, 2023, Roivant Sciences surprised investors with its impressive Q4 performance, leading to a surge in its stock prices. The company’s financial results for the fourth quarter and fiscal year ending March 31, 2022, revealed a net loss of $352.01 million, marking a 15.01% decline compared to the previous year. Despite this setback, Roivant Sciences managed to surpass analysts’ predictions, with earnings per share of -$1.78 over the past four quarters. The company’s Q4 loss was offset by a remarkable 44.56% increase in revenue, surpassing all expectations.

After 'transformative' year, Roivant aims to challenge bigger rivals in inflammation and immunology

Roivant shares gain more than 10% after narrower-than-expected quarterly loss. After surviving some turbulent market conditions in its first years as a public company, Roivant Sciences Ltd. ROIV, is taking on industry behemoths as it develops new treatments for ulcerative colitis, Crohn’s disease and other conditions.

Roivant Reports Positive Results in Phase II Ulcerative Colitis Trial

Thursday, Roivant Sciences announced positive results from a Phase IIb trial of a closely watched treatment for different kinds of inflammatory bowel disease. RVT-3101, a monthly subcutaneously administered anti-TL1A antibody, showed positive results in patients with moderate to severe ulcerative colitis.

Five things for pharma marketers to know: Friday, June 23, 2023

Roivant Sciences released Phase IIb data for RVT-3101, the UC program it acquired from Pfizer late last year, showing that the drug’s effects could be maintained for up to a year. It’s confirmation of earlier data showing success at 14 weeks — a statistically significant finding, Roivant said in January.

As Roivant readies for a UC clash with Merck, CEO Matt Gline is candid about keeping a competitive edge

Roivant CEO Matt Gline is getting ready for a development showdown with Merck and its newly acquired ulcerative colitis drug from Prometheus Biosciences.

Roivant rises after long-term data for ulcerative colitis candidate

Why Roivant Sciences Stock is Trading Higher Today

Roivant Sciences Ltd released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with moderate to severe ulcerative colitis.

The company says this is the first-ever long-duration data reported for an anti-TL1A antibody.

Roivant reports more positive data for inflammation drug

Some analysts see the new results as further confirmation that Roivant’s medicine could become a blockbuster treatment for inflammatory bowel disease.

Roivant’s longer-term colitis data set a bar in emerging TL1A class

New Phase IIb ulcerative colitis data showing rising remission rates over time suggest a molecule from Roivant and Pfizer has exceeded efficacy expectations, driving a gain in market cap of about $334 million and setting a bar for others in the class.

Roivant Sciences shares gain after ulcerative colitis treatment shows longer-term results

Shares of Roivant Sciences Ltd. ROIV, 1.25% gained 14% in premarket trading Thursday after the company released new long-duration data from a study of its monoclonal antibody RVT-3101 in adults with ulcerative colitis. The treatment resulted in improved clinical remission of 36% at week 56, versus 29% at week 14, the company said in a release.

Why Roivant Sciences Stock Is Perking Up Today

Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock.

Goldman Sachs Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

In a report released today, Corinne Jenkins from Goldman Sachs maintained a Buy rating on Roivant Sciences (ROIV – Research Report), with a price target of $14.00. The company’s shares opened today at $10.05.

Roivant Plots ‘Streamlined’ Phase III As Ulcerative Colitis Data Raise Blockbuster Potential

The company announced data from the Phase IIb TUSCANY-2 trial of RVT-3101, which is in a tight race with PRA023 from Prometheus, which Merck recently acquired for $10.8bn.

A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout

"Our expectations for this chronic data were categorically exceeded with significant improvements seen in patients receiving the expected Phase 3 dose across all key (effectiveness) metrics at week 56 vs. at week 14," Roivant Chief Executive Matt Gline said in a written statement.

Roivant shares climb on longer-term ulcerative colitis drug results

Shares of Roivant Sciences were up 17% in premarket trade Thursday after the company released new longer-duration data from a Phase IIb study of RVT-3101 in adults with ulcerative colitis. "These results continue to support RVT-3101's potential as a first-in-class anti-TL1A antibody, demonstrating sustained efficacy across a broad dose range measured at 56 weeks," the company said.

Roivant rises on growing hopes for novel immunology mechanism

After impressive induction results in January, maintenance data from the same trial of Roivant’s RVT-3101 have increased excitement about the novel TL1A-targeting mechanism. Ulcerative colitis patients showed ongoing improvements on clinical and endoscopic remission endpoints in the phase 2b Tuscany-2 trial, with “compelling efficacy” across cohorts at 56 weeks; Roivant executives described the 36% endoscopic remission rate in biomarker-positive patients treated with the anticipated phase 3 dose as unparalleled.

Roivant Sciences: Financial Fortitude And Pipeline Advancements Demonstrate Strength

The breadth of Roivant's (NASDAQ:ROIV) product pipeline and the versatility of its business model substantiate its strength as a biopharmaceutical player. The success of VTAMA and the potential of RVT-3101, along with other promising products in late-stage clinical trials, underscore Roivant's dedication to pioneering healthcare solutions. Its robust financials and innovative research model further enhance its investment appeal. Hence, Roivant Sciences presents a compelling investment proposition for investors seeking to capitalize on cutting-edge therapeutics and a unique business approach in the biopharmaceutical sector.

Roivant Sciences: Coming Nicely To The Boil With Multiple Opportunities

Roivant's Pipeline & Products Suggest Blockbuster Revenues Await - & Perhaps Significantly More - A Strong, Albeit Higher Risk Investment Opportunity

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

Finger On The Pulse: The State Of Biopharma Leadership

In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.

Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?

Last December, Pfizer (NYSE: PFE) essentially out-licensed its tumor necrosis factor-like ligand 1A (TL1A), PF-06480605 (now RVT-3101), to Roivant Sciences (NASDAQ: ROIV) by forming a new company with the precision drugmaker. Per the terms of the deal Pfizer owns a 25% equity stake in the new company, along with the drug's commercial rights outside of the U.S. and Japan.

Small Molecule Immunotherapy

In the wake of the Covid-19 pandemic, there’s one issue that unites hospitals around the globe: health worker burnout. As part of its strategy to help its existing healthcare customers—and woo new ones—Amazon’s cloud division has selected 23 health tech startups from a pool of 500 applications to participate in its latest healthcare accelerator program focused on workforce issues.

Roivant’s Covant Therapeutics and BI join forces to explore covalent drug space

With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders.

Roivant Sciences has added another branch to its family tree, unveiling Covant Therapeutics with a $10 million upfront commitment from Boehringer Ingelheim to turn up the heat in cancer.

Roivant stock jumps as skin cream Vtama meets main goal of phase 3 eczema trial

Dermavant Sciences' Vtama cream met the main goal of achieving clearer skin in a phase 3 trial to treat patients as young as two years old, and adults with atopic dermatitis (AD).

Roivant’s stock rallies on new data for dermatitis drug

Roivant's Vtama Meets Key Endpoints in Atopic Dermatitis Study >ROIV

Roivan­t's ul­cer­a­tive col­i­tis drug from Pfiz­er shows promis­ing da­ta in ear­ly read­out

Roivant’s ulcerative colitis drug acquired from Pfizer last month has already produced positive data in the first readout of the Phase IIb trial.

Roivant Sciences: 'Fiercely Economic Actor' With Multiple Catalysts

Advancing Medicines That Matter, Matt Gline, CEO, Roivant Sciences

Matt Gline is the CEO of Roivant Sciences, a company that delivers innovative medicines and technologies to patients by building Vants – nimble, entrepreneurial biotech and healthcare technology companies.

Collecting Pharma’s Scraps Can Pay Off for This Biotech

Roivant Is Striving Towards New Standards Of Care

With numerous highly anticipated data readouts due over 2023, the spotlight is on Roivant like never before. CEO Matt Gline enlightens In Vivo on the firm’s ‘vant’ subsidiaries, its in-house drug development strategies and the future of its Vtama psoriasis treatment.

Matt Gline wants you to stop thinking of Roivant as a discard company. In 2023, he'll prove it

Matt Gline has had enough of the quips. Over the course of his seven-year tenure at Roivant Sciences—the last two as CEO—he's fended off what he thinks are condescending characterizations that the “vant” parent company is a discard-reliant pharma and prognostications about the potential of the drugs it works on.

Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant

Failure is part of building a biotech, and Roivant’s CEO says it provides a blueprint for managing scientifically risky bets. Roivant Sciences is hoping for a big year.

JPM23: Roivant CEO says 2023 shaping up to be 'single most exciting year' for new readouts

Much has been said about the tumultuousness of the biotech market in 2022 and how the industry and associated innovation will fare in the new year. Roivant Sciences CEO Matt Gline has heard the prognosticating and, at this year’s J.P. Morgan Healthcare Conference, he had a concise message on behalf of his company: We’re moving up.

Five things for pharma marketers to know: Thursday, January 5, 2023

Eli Lilly struck a $55 million deal with Capsida Biotherapeutics to develop gene therapies for central nervous system diseases. Under the agreement, Eli Lilly’s Prevail, which it acquired in 2021 to develop its gene therapy unit, will spearhead early development and Capsida will lead discovery.

Roivant Sciences Sees Positive Trial Results for RVT-3101 Antibody

Fresh from Pfizer deal, Roivant posts 'best-in-class' ulcerative colitis data on rival to Prometheus prospect

Roivant Sciences has shown its hand in the red-hot race for a new ulcerative colitis market. Weeks after Prometheus Biosciences wowed investors, and with the ink on its deal with Pfizer to enter the race still drying, Roivant has shared phase 2b data it claims position it as a best-in-class contender.

Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate

Roivant Sciences (NASDAQ: ROIV) announced results from the induction period of the TUSCANY-2 Phase 2b study of RVT-3101 (previously PF-06480605), a once-monthly anti-TL1A antibody for ulcerative colitis.

Roivant reports positive mid-stage data for ulcerative colitis therapy

U.K.-based biotech Roivant Sciences (NASDAQ:ROIV) announced Wednesday that its Phase 2b trial for subcutaneous ulcerative colitis therapy RVT-3101 generated statistically significant and clinically meaningful efficacy results at each dose level.

Roivant reveals positive data for IBD drug, intensifying rivalry with Prometheus

A race to develop a new kind of treatment for inflammatory bowel disease heated up Wednesday, with the release of positive data for an experimental drug that’s backed by Pfizer and Roivant Sciences.

Quick Takes: Roivant TL1A mAb heading into Phase III in ulcerative colitis

A Phase III showdown between anti-TL1A mAbs for ulcerative colitis is shaping up for 2023 with positive Phase IIb data for RVT-3101 from Roivant Sciences Ltd. (NASDAQ:ROIV) announced less than a month after Prometheus Biosciences Inc. (NASDAQ:RXDX) reported Phase II results for PRA023.

Roivant-Pfizer inflammatory bowel drug hits high expectations in mid-stage study

An experimental inflammatory bowel disease medicine that serves as the basis for a partnership between Roivant Sciences and Pfizer met high expectations for a Phase 2 clinical trial data released.

Pfizer Returns To Roivant As Development Partner For A Second Time